16 completed. 16 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 16 |
| Phase 2 | 2 | Completed 2 |
Follow Chronic Urticaria: new trials by email Literature Review of Chronic Urticaria trials Research Report on Chronic Urticaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS) JTE-162 - Cryopyrin-associated Periodic Syndromes (CAPS) | Phase 1 | Completed | Akros Pharma Inc. | 5 | 2026-02-02 | 2026-10-09 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single and Multiple Doses of HRS-3095 Oral Administration in Healthy Subjects, as Well as the Effect of HRS-3095 on CYP3A4 Metabolic Enzymes HRS-3095 Tablet, HRS-3095 Placebo Tablet - Chronic Spontaneous Urticaria | Phase 1 | Completed | Chengdu Suncadia Medicine Co., Ltd. | 82 | 2025-11-10 | 2026-06-12 |
| Open-Label Extension Study for Subjects With H1 Antihistamine Refractory Chronic Spontaneous Urticaria Completing Study AK006-001 AK006 IV - Chronic Spontaneous Urticaria | Phase 1 | Completed | Allakos Inc. | 29 | 2024-08-28 | 2025-08-27 |
| Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU) Briquilimab, Placebo - Chronic Spontaneous Urticaria | Phase 1 / Phase 2 | Completed | Jasper Therapeutics, Inc. | 87 | 2023-11-29 | 2026-08-06 |
| Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria Oral EP262 - Chronic Inducible Urticaria | Phase 1 | Completed | Escient Pharmaceuticals, Inc | 33 | 2023-08-30 | 2024-12-09 |
| Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria AK006-IV, Placebo-IV, AK006-SC - Healthy Participants, Chronic Spontaneous Urticaria | Phase 1 | Completed | Allakos Inc. | 136 | 2023-08-28 | 2025-06-03 |
| A Single Dose, Phase 1 Study of YH35324 in Patients with Various Allergic Diseases YH35324, Omalizumab, Placebo - Allergic Disease, Chronic Spontaneous Urticaria | Phase 1 | Completed | Yuhan Corporation | 30 | 2023-08-23 | 2024-11-22 |
| A Study of Single and Multiple Doses of LP-003 in Healthy Adult Participants LP-003 Dose 1 (Single), LP-003 Dose 2 (Single), LP-003 Dose 3 (Single) - Chronic Spontaneous Urticaria | Phase 1 | Completed | Longbio Pharma | 60 | 2022-07-13 | 2025-12-12 |
| Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria. TLL018 tablets - Chronic Spontaneous Urticaria | Phase 1 | Completed | Hangzhou Highlightll Pharmaceutical Co., Ltd | 41 | 2022-05-10 | 2024-03-01 |
| Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1% Fexofenadine Hydrochloride Topical Lotion 1% (OP2101) - Atopic Dermatitis, Atopic Dermatitis Eczema | Phase 1 | Completed | OrchestratePharma GmbH | 12 | 2022-04-01 | 2023-03-29 |
| A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria CDX-0159, Normal Saline - Chronic Spontaneous Urticaria | Phase 1 | Completed | Celldex Therapeutics | 45 | 2020-09-24 | 2023-07-19 |
| Safety and Tolerability, Pharmacokinetic and Pharmacodynamic Study With IZD334 IZD334, Placebos - Healthy Volunteers, Cryopyrin Associated Periodic Syndrome | Phase 1 | Completed | Inflazome UK Ltd | 64 | 2019-09-13 | 2020-03-02 |
| Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU Patients UB-221 - Urticaria Chronic | Phase 1 | Completed | United BioPharma | 15 | 2019-04-09 | 2022-05-13 |
| A Dose-Block Randomized, Placebo Controlled (Double-blind), Active Controlled(Open-label), Dose-escalation Study HL2351, Kineret(Anakinra) - Healthy Volunteers | Phase 1 | Completed | Handok Inc. | 58 | 2014-05-01 | 2015-10-06 |
| Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjunctivitis (AR) or Chronic Urticaria (CU) Bilastine - Allergic Rhinoconjunctivitis, Chronic Urticaria | Phase 1 / Phase 2 | Completed | Faes Farma, S.A. | 36 | 2010-01-01 | 2012-09-26 |
| The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria Kineret (anakinra) - Familial Cold Urticaria | Phase 1 | Completed | Nova Scotia Health Authority | 8 | 2005-09-01 | 2022-11-08 |
Cryopyrin-Associated Periodic Syndromes (4) · Pruritus (3) · Urticaria (3) · Chronic Inducible Urticaria (2) · Arthritis, Rheumatoid (1) · Chronic Disease (1) · Cold Urticaria (1) · Dermatitis (1) · Dermatitis, Atopic (1) · Eczema (1) · Erythema (1) · Exanthema (1) · Hypersensitivity (1) · Immune System Diseases (1)
Disease Attributes (16) · Hypersensitivity, Immediate (16) · Pathological Conditions, Signs and Symptoms (16) · Skin and Connective Tissue Diseases (16) · Chronic Disease (15) · Hypersensitivity (15) · Immune System Diseases (15) · Pathologic Processes (15) · Skin Diseases (15) · Skin Diseases, Vascular (15) · Urticaria (13) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Genetic Diseases, Inborn (5) · Skin Diseases, Genetic (5)
Interleukin 1 Receptor Antagonist Protein (2) · Injections (1) · Omalizumab (1) · Saline Solution (1) · Single Person (1) · bilastine (1)
Allakos Inc. (2) · Akros Pharma Inc. (1) · Celldex Therapeutics (1) · Chengdu Suncadia Medicine Co., Ltd. (1) · Escient Pharmaceuticals, Inc (1) · Faes Farma, S.A. (1) · Handok Inc. (1) · Hangzhou Highlightll Pharmaceutical Co., Ltd (1) · Inflazome UK Ltd (1) · Jasper Therapeutics, Inc. (1) · Longbio Pharma (1) · Nova Scotia Health Authority (1) · OrchestratePharma GmbH (1) · United BioPharma (1) · Yuhan Corporation (1)
Canada (5) · United States (5) · Germany (4) · China (3) · Australia (2) · South Korea (2) · Bangladesh (1) · Netherlands (1) · Spain (1) · Sweden (1) · Taiwan (1)
Gunilla Hedlin, Prof. Dr. (1) · Hae-Sim Park (1) · Hyeong Ki Lee, Professor (1) · Jason Lickliter, MBBS, PhD (1) · Lennart Nordvall, Prof. Dr (1) · Noel E Cranswick, Prof. Dr. (1) · Peter Le Souef, Prof. Dr. (1) · Stefan Zielen, Prof. Dr. (1) · Ulrich Wahn, Prof. Dr. (1) · Xueying Ding (1)
2009 (1), 2023 (1)